Acute myeloid leukemia
Conditions
Interventions
Group A:HAD scheme
Group B:CHG scheme
Group C:DHAD scheme
Group D:DCHG scheme
Sponsors
Shanxi Bethune Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old and 5%; (3) extramedullary recurrence. 5. Inclusion criteria of had and Dhad regimens: AML patients with active hyperplasia or FLT3 / ITD +, FLT3 / TKD + were preferred to have regimen; If AML patients with a history of prodromal MDS or MPD, or with complex karyotypes (>= 3 kinds), or with typical methylation gene mutation, Dhad regimen (plus decitabine 15mg / m2 / D, D1-5) should be preferred. 6. Inclusion criteria of CHG and dchg regimens: Patients with AML whose myelogram showed decreased proliferation or whose white blood cells were lower than normal range were preferred to CHG regimen. If AML patients with a history of prodromal MDS or MPD, or with complex karyotypes (>= 3 kinds), or with typical methylation gene mutation, dchg regimen (plus decitabine 15mg / m2 / D, D1-5) should be preferred. 7. The ECOG-ps score of the eastern oncology collaboration group was 0-2. 8. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Accompanied by cerebral hemorrhage; 2) Pregnancy; 3) Mental illness or other conditions that cannot be carried out as planned; 4) Severe arrhythmia, abnormal ECG (QT > 500ms).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate;Relapse Rate;Treatment related mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Event free survival;Overall survival;Peripheral blood primitive cell count in agranulocytosis;Efficacy of different subgroups;Safety of chemotherapeutic drugs; | — |
Countries
China
Contacts
Public ContactTao Wang
Shanxi Bethune Hospital of Shanxi Medical University
Outcome results
None listed